Summary of Triple Phenotyping Study in 13 AML Patients at Diagnosis
| Phenotype . | % NC . | Potential Fold Enrichment7-150 . |
|---|---|---|
| CD34+/CD38−/HLA-DR− | 0.3 ± 0.1 | >300 |
| CD34+/CD38−/CD71− | 0.7 ± 0.4 | >100 |
| CD34+/CD71−/HLA-DR− | 1.5 ± 0.9 | 67 |
| CD34+/CD38−/CD33− | 2 ± 1 | 50 |
| CD34+/HLA-DR−/CD33− | 5 ± 3 | 20 |
| CD34+/CD71−/CD33− | 6.4 ± 3 | 15 |
| Phenotype . | % NC . | Potential Fold Enrichment7-150 . |
|---|---|---|
| CD34+/CD38−/HLA-DR− | 0.3 ± 0.1 | >300 |
| CD34+/CD38−/CD71− | 0.7 ± 0.4 | >100 |
| CD34+/CD71−/HLA-DR− | 1.5 ± 0.9 | 67 |
| CD34+/CD38−/CD33− | 2 ± 1 | 50 |
| CD34+/HLA-DR−/CD33− | 5 ± 3 | 20 |
| CD34+/CD71−/CD33− | 6.4 ± 3 | 15 |
Abbreviation: NC, nucleated cells.
Potential fold enrichment, calculated from the % of NC. This is equal to the degree of enrichment of primitive cells, which could be achieved by using a sorting strategy to select cells with this phenotype, providing all cells of interest were contained within this subfraction.